These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 15037444

  • 1. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 2. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [Abstract] [Full Text] [Related]

  • 3. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 4. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 19; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 5. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 6. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML.
    Ann Rheum Dis; 2010 Nov 15; 69(11):2002-8. PubMed ID: 20511613
    [Abstract] [Full Text] [Related]

  • 7. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
    Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.
    Ann Rheum Dis; 2006 Feb 15; 65(2):201-8. PubMed ID: 16014677
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 15; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 9. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J.
    Z Rheumatol; 2003 Jun 15; 62(3):264-73. PubMed ID: 12827403
    [Abstract] [Full Text] [Related]

  • 10. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 11. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug 15; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 12. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar 15; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J.
    Arthritis Rheum; 2000 Jun 15; 43(6):1346-52. PubMed ID: 10857793
    [Abstract] [Full Text] [Related]

  • 15. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J.
    Rheumatology (Oxford); 2011 Aug 15; 50(8):1466-72. PubMed ID: 21441550
    [Abstract] [Full Text] [Related]

  • 16. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.
    Rheumatology (Oxford); 2005 Oct 15; 44(10):1277-81. PubMed ID: 16105913
    [Abstract] [Full Text] [Related]

  • 17. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J, Baclé-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM.
    J Rheumatol; 2012 Jul 15; 39(7):1418-23. PubMed ID: 22707611
    [Abstract] [Full Text] [Related]

  • 18. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.
    Ann Rheum Dis; 2010 Jun 15; 69(6):1065-71. PubMed ID: 19740906
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb 15; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 20. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J.
    Arthritis Rheum; 2010 May 15; 62(5):1290-7. PubMed ID: 20461780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.